Table 1.
Characteristics of T2DM trials in the US and the UK
| Study Characteristics | # of US-Based Trials (%) (N = 1,671) | # of UK-Based Trials (%) (N = 209) |
|---|---|---|
| Study phase | -- | -- |
| Phase 0 | 9 (0.5%) | 0 (0%) |
| Phase 1 | 299 (17.9%) | 22 (10.5%) |
| Phase 2 | 349 (20.9%) | 23 (11.0%) |
| Phase 3 | 495 (29.6%) | 77 (36.8%) |
| Phase 4 | 189 (11.3%) | 33 (15.8%) |
| Unspecified | 394 (23.6%) | 57 (27.3%) |
| Sponsor type | -- | -- |
| NIH | 23 (1.4%) | 0 (0%) |
| Industry | 1,060 (63.4%) | 134 (64.1%) |
| Other U.S. Federal Agency | 30 (1.8%) | 0 (0%) |
| Other | 558 (33.4%) | 75 (35.9%) |
| Intervention type | -- | -- |
| Drug | 1,204 (72.1%) | 152 (72.7%) |
| Procedure | 34 (1.9%) | 2 (1.0%) |
| Biological | 32 (1.9%) | 4 (1.9%) |
| Device | 49 (2.9%) | 9 (4.3%) |
| Behavioral | 194 (11.6%) | 17 (8.1%) |
| Dietary supplement | 49 (2.9%) | 14 (6.7%) |
| Genetic | 1 (0.1%) | 0 (0%) |
| Radiation | 1 (0.1%) | 0 (0%) |
| Other | 107 (6.4%) | 11 (5.3%) |
| Primary purpose | -- | -- |
| Basic science | 108 (6.5%) | 14 (6.7%) |
| Diagnostic | 20 (1.2%) | 2 (2.0%) |
| Education/Counseling/Training | 1 (0.1%) | 0 (0%) |
| Health services research | 40 (2.4%) | 3 (1.4%) |
| Prevention | 99 (5.9%) | 17 (8.1%) |
| Screening | 4 (0.2%) | 0 (0%) |
| Supportive care | 33 (2.0%) | 5 (2.4%) |
| Treatment | 1,268 (75.9%) | 161 (77.0%) |
| Unspecified | 98 (5.9%) | 7 (3.3%) |
| Allocation | -- | -- |
| Randomized | 1,452 (86.9%) | 190 (90.1%) |
| Non-Randomized | 107 (6.4%) | 3 (1.4%) |
| Unspecified | 112 (6.7%) | 16 (7.7%) |